Current Options in Obesity Treatment — A 2026 Comparison

Obesity treatment offers a substantial range of options in 2026. Which one is right for you? In this article we compare the available treatment categories using evidence-based data — not superlative claims, but real clinical figures.

---

Why Does 2026 Matter?

This year, two critical developments changed the rules of the game in obesity treatment:

1. Allurion FDA PMA Class III Approval (February 2026): The swallowable gastric balloon, which requires no endoscopy, received full approval by completing the Premarket Approval (PMA) process that the FDA mandates for Class III medical devices. PMA is the FDA's regulatory pathway requiring comprehensive clinical evidence for devices; this approval is based on a multicenter clinical data program (Data on File, Allurion 2026).

2. GLP-1 + intragastric balloon combination research: Preliminary findings that have not yet undergone peer review (n=76, manufacturer report, preliminary) suggest the potential of a combined approach. These data are not yet conclusive, and the application is determined individually, only through physician evaluation; concrete TBWL rates cannot be presented as a clinical expectation until they are confirmed by validated publications.

---

Treatment Categories

1. Lifestyle Intervention

What: Diet, exercise, behavioral coaching. Who it's for: Individuals who are mildly overweight (BMI 25–30) and have motivation and a support infrastructure.

Advantages:

• Generally the lowest procedural risk profile compared with invasive methods
• No cost (on its own)
• Synergistic with all other methods

Disadvantages:

• Limited long-term success rate on its own
• Hard to sustain without structural support (a program, a physician)

---

2. GLP-1 Receptor Agonists

What: Hormonal appetite-regulating medications. Molecules developed for diabetes that are also approved for obesity. Who it's for: BMI ≥ 30, or BMI ≥ 27 + a metabolic comorbidity.

Clinical data (weight loss):

• Mean 12–15% TBWL (higher at high doses)

Critical disadvantage:

• An average +5.63 kg regain when the medication is stopped (18 RCTs, 3,771 patients; EClinicalMedicine 2025, PMID: 41399474)
• Requires continuous use — long-term cost is high
• Side effects: nausea, vomiting, constipation (common at the start)

"The effectiveness of GLP-1 RAs largely depends on continuous use. The risk of weight regain is high when the medication is discontinued."

---

3. Swallowable Gastric Balloon (Allurion)

What: A 16-week intragastric balloon program that requires no endoscopy. Who it's for: BMI 27–40, those who carry anesthesia/surgical risk, and those who prefer a minimally invasive option.

Clinical data:

• Mean TBWL: 14.9% (Ienca et al., 1,770 patients, PMID: 32279182)
• Weight maintenance at 1 year: 95% (Caballero et al., 522 patients, PMID: 40676353)
• Serious adverse events: <0.2%
• Real-world: Multicenter 2025 (PMID: 41037243)

Advantages:

• One-time cost — no ongoing medication expense
• No anesthesia, no endoscopy
• The 16-week program supports behavioral change
• FDA PMA Class III approved (February 2026)

Disadvantages:

• An adaptation period with nausea in the first 1–2 weeks
• Effect is limited in duration — it ends on its own when the program finishes
• May not be sufficient on its own at very high BMI (>40)

---

4. Endoscopic Bariatric Procedures

What: Endoscopic sleeve gastroplasty, conventional endoscopic gastric balloons. Who it's for: BMI 30–40, individuals who do not want to move to surgery.

Features:

• Requires anesthesia
• Longer procedure time compared with Allurion
• Reversible (balloon removal is required)

---

5. Bariatric Surgery

Subtypes: Sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric band. Who it's for: BMI ≥ 35 + comorbidity; or BMI ≥ 40.

Clinical data:

• TBWL: 25–35% (a high range among the categories; supported by long-term follow-up data)
• 10-year follow-up data are available

Advantages:

• It is an option with one of the highest reported mean TBWL among treatment categories, and long-term weight maintenance is documented with follow-up data extending to 10 years
• Can achieve diabetes remission

Disadvantages:

• General anesthesia + surgical risk
• Permanent anatomical change (difficult to reverse)
• Risk of serious complications: anastomotic leak, nutritional deficiencies
• Long recovery period

---

Comparison Table

Criterion	Lifestyle	GLP-1 RA	Allurion Balloon	Bariatric Surgery
Mean TBWL	5–10%	12–15%	14.9%	25–35%
Weight maintenance at 1 year	Variable	Low (if medication stopped)	95%	High
Anesthesia	None	None	None	Required
Reversibility	Full	Full	Full	Limited
Ongoing cost	Low	High	None	None
FDA approval	—	Approved	PMA Class III	Approved
BMI range	Any	≥27+comorb	27–40	≥35+comorb

---

Who Should Consider Which Option?

Lifestyle + support program:

• BMI between 25–30
• At a level that does not yet require medical intervention

GLP-1 RA:

• BMI ≥ 30 or ≥ 27 + diabetes/hypertension
• Ready for long-term medication use
• Ongoing medical follow-up is possible

Allurion Gastric Balloon:

• BMI between 27–40
• No anesthesia/surgical risk or preference
• Commitment to the 16-week program
• Preference for a one-time intervention

Allurion + GLP-1 combination (research stage):

• Suitable for both products, with a high target weight loss
• The protocol should be determined with a physician

Bariatric surgery:

• BMI ≥ 35 + comorbidity or ≥ 40
• No success achieved with conservative methods
• A general condition that can tolerate surgical risk

---

A Trend to Watch in 2026: Combination Therapies

Researchers are now moving beyond a single method. Combination approaches — for example, GLP-1 RA + balloon — carry the potential to increase both weight loss and long-term maintenance.

However, combination protocols are still at the research stage. Decisions should be made considering individual preferences, risks, and costs.

---

Conclusion: There Is No "Best" Treatment — There Is the Right Treatment

There is no single "best" option in obesity treatment. The right option is determined by your BMI, your medical history, your lifestyle, and your long-term goals.

We recommend making this assessment together with a specialist physician.

Individual results may vary. Make all medical decisions together with your specialist physician.

Further reading:

• The Complete 2026 Guide to the Swallowable Gastric Balloon →
• What Happens When You Stop GLP-1? →
• How Much Weight Can You Lose with a Gastric Balloon? →
• Clinical Evidence →
• Calculate BMI →

---

This content is for general informational purposes. Consult your specialist physician for treatment decisions.

Authorized Clinics in a City Near You

You can access the Allurion Program at more than 60 authorized clinics across Türkiye. For clinics in major cities:

• Gastric balloon clinics in İstanbul →
• Gastric balloon clinics in Ankara →
• Gastric balloon clinics in İzmir →
• Gastric balloon clinics in Antalya →
• Find a specialist in all cities →